ACTRN12613000566730
Recruiting
未知
In men receiving androgen-deprivation therapy for histologically confirmed prostate cancer, what is the natural course of hot flash symptoms?
A/Professor Henry Woo0 sites20 target enrollmentMay 20, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- atural course of hot flashes in men with prostate cancer, receiving ADT for the first time.
- Sponsor
- A/Professor Henry Woo
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men with histologically confirmed and hormone\-naive prostate cancer, being commence on androgen\-deprivation therapy for the first time.
Exclusion Criteria
- •Exclusion criteria include previous androgen\-deprivation therapy, participant inability to complete a hot flash score independently, and an ECOG status of 2 or more.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 4
The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from Chinaprostate cancerCancer - ProstateACTRN12613000107729Changhai Hospital, Second Military Medical University100
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004853-26-FITurku University Hospital35
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)EUCTR2017-002345-29-FITurku University Hospital5
Active, not recruiting
Not Applicable
Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the bodyMetastatic hormone-sensitive prostate cancerCancerISRCTN66357938niversity College London4,914
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.ACTRN12617001116314St Vincent's Hospital, Sydney20